Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Key Players companies in Ribociclib
by Most Patent Filings in the world in 2019

The Ribociclib top 20 is Discovery PatSnap’ annual ranking of the top 20 Most Patent Filings Ribociclib Key Players in the world. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2019, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Ribociclib (trade name Kisqali) is an inhibitor of cyclin D1/CDK4 and CDK6, and is used for the treatment of certain kinds of breast cancer. It is also being studied as a treatment for other drug-resistant cancers. It was developed by Novartis and Astex Pharmaceuticals.
#
Company Name
Region
Tech Topics
Total
1
Basel-Stadt, Switzerland
Dosage form,Health care,Medicine,
...[+2]
Patent: 54
2
Ontario, Canada
Patent: 4
3
Patent: 4
4
Patent: 3
5
Oncology,Medicine,Health care,
...[+2]
Patent: 3
6
Patent: 2
7
Patent: 2
8
Trade partner,Corporate social responsibility,Medicine,
...[+2]
Patent: 2
9
Patent: 2
10
Patent: 2
11
Patent: 2
12
Tel Aviv, Israel
Gastrointestinal agent,Immunotherapy,Clinical trial,
...[+2]
Patent: 2
13
Contract research organization,Health care,Liposome,
...[+2]
Patent: 2
14
Patent: 2
15
Noord-Brabant, Netherlands
Patent: 2
16
Health care,Clinical trial,Drug,
...[+2]
Patent: 1
17
Patent: 1
18
New Ventures,Medicine,Health care,
...[+2]
Patent: 1
19
Diabetology,Cephalosporin,Biotechnology,
...[+2]
Patent: 1
20
Patent: 1
Page generation time: Jul 07 2025